MC2 TCR T cells therapy (Erasmus Medical Center)

N/A

Report date: 2024/07/18 14:12:04

Base Information

Drug NameMC2 TCR T cells therapy (Erasmus Medical Center)

Drug Alias NameMAGE-C2/HLA-A2 TCR T cells (Erasmus Medical Center)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Cell therapy > Donor > Autologous

Mechanisms of ActionCell replacementsAnti-HLA-A2Melanocortin receptor 2 modulators

TargetsMelanocortin receptor 2HLA Class I Histocompatibility Antigen, A-2 alpha Chain

Therapy Area/IndicationsUveal melanomaHead and Neck NeoplasmsMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlands

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesErasmus Medical Center

China Registration ClassN/A

Develop Information

Active CompaniesErasmus Medical Center

Inactive CompaniesN/A

Active IndicationsUveal melanomaHead and Neck NeoplasmsMelanoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A